S21 Stock Overview
Develops, produces, and sells wound healing products for burns and chronic wounds in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
S2Medical AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.0007 |
| 52 Week High | SEK 0.011 |
| 52 Week Low | SEK 0.0002 |
| Beta | 0.81 |
| 11 Month Change | -50.00% |
| 3 Month Change | -77.42% |
| 1 Year Change | -65.00% |
| 33 Year Change | -99.85% |
| 5 Year Change | -99.94% |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| S21 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -12.5% | 2.4% | 0.8% |
| 1Y | -65.0% | -5.0% | 9.1% |
Return vs Industry: S21 underperformed the German Medical Equipment industry which returned -5% over the past year.
Return vs Market: S21 underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| S21 volatility | |
|---|---|
| S21 Average Weekly Movement | 51.0% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: S21's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: S21's weekly volatility has decreased from 234% to 51% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 17 | Petter Sivlér | www.s2m.se |
S2Medical AB (publ) develops, produces, and sells wound healing products for burns and chronic wounds in Sweden. It offers Epiprotect 2117, a synthetic allograft/xenograft substitute; Epiprotect Ulcer, a wound dressing consisting of a thin film of biosynthetic cellulose polymer intended to be used as a protective barrier for superficial wounds and deep wounds that have breached the dermis, as well as used as a temporary coverage for deep extensive wounds before transplantation or other surgical intervention. The company also provides washable, durable, waterproof, and self-adhesive bandages under the INSTABIND brand name, as well as NO SMELL, a perfume-free odour remover.
S2Medical AB (publ) Fundamentals Summary
| S21 fundamental statistics | |
|---|---|
| Market cap | €250.06k |
| Earnings (TTM) | -€161.38k |
| Revenue (TTM) | €953.93k |
0.3x
P/S Ratio-1.5x
P/E RatioIs S21 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| S21 income statement (TTM) | |
|---|---|
| Revenue | SEK 10.99m |
| Cost of Revenue | SEK 1.54m |
| Gross Profit | SEK 9.45m |
| Other Expenses | SEK 11.31m |
| Earnings | -SEK 1.86m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0065 |
| Gross Margin | 85.99% |
| Net Profit Margin | -16.92% |
| Debt/Equity Ratio | 0% |
How did S21 perform over the long term?
See historical performance and comparison